Severity: Warning
Message: file_get_contents(https://...@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 197
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 197
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 271
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 1075
Function: getPubMedXML
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3195
Function: GetPubMedArticleOutput_2016
File: /var/www/html/application/controllers/Detail.php
Line: 597
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 511
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 317
Function: require_once
98%
921
2 minutes
20
Purpose: This study aimed to clarify the molecular mechanisms of Qingre Jiedu Decoction (QJD), a traditional Chinese medicine (TCM), in treating infectious mononucleosis (IM). By combining network pharmacology and clinical trial validation, the research sought to understand how QJD interacts with biological pathways to combat IM.
Methods: The research team identified active compounds and their targets in QJD using databases like TCMSP and STITCH. Genes related to IM were sourced from NCBI and DisGeNET. These data were used to construct a protein-protein interaction (PPI) network with STRING, visualizing interactions between QJD targets and IM-related genes. Functional enrichment analyses were conducted, including GO biological process analysis via Cytoscape ClueGo and KEGG pathway analysis using R's Clusterprofile package. A clinical trial involving 97 pediatric IM patients (53 in the experimental group, 44 in the control group) evaluated QJD's real-world efficacy.
Results: The study identified 156 active compounds and 401 targets in QJD, along with 15 potential therapeutic targets for IM. In the clinical trial, the experimental group showed a significantly higher negative rate of plasma EBV (Epstein-Barr virus)-DNA post-treatment, indicating a stronger antiviral effect. Peripheral blood lymphocyte counts, CD3 percentage, and CD8 percentage decreased in the experimental group, suggesting an immunomodulatory effect. Additionally, levels of inflammatory cytokines (IL-6, IL-1β, TNF-α) were significantly reduced post-treatment, supporting QJD's anti-inflammatory properties.
Conclusion: QJD's multi-component effects contribute to its antiviral activity against EBV by modulating cytokine-mediated signaling pathways. This finding provides a scientific basis for QJD's clinical use in IM and underscores the potential of integrating network pharmacology with clinical trials to elucidate TCM mechanisms.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12297019 | PMC |
http://dx.doi.org/10.2147/DDDT.S492448 | DOI Listing |